{
    "clinical_study": {
        "@rank": "134327", 
        "arm_group": [
            {
                "arm_group_label": "Fosaprepitant 150 mg", 
                "arm_group_type": "Experimental", 
                "description": "Cycle 1: Fosaprepitant 150 mg (or weight-adjusted equivalent for children <12 years of age), administered intravenously (IV) plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 150 mg (or weight-adjusted equivalent for children <12 years of age), administered IV plus a 5-hydroxytryptamine 3 (5-HT3) antagonist."
            }, 
            {
                "arm_group_label": "Fosaprepitant 60 mg", 
                "arm_group_type": "Experimental", 
                "description": "Cycle 1: Fosaprepitant 60 mg (or weight-adjusted equivalent for children <12 years of age), administered IV plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 150 mg (or weight-adjusted equivalent for children <12 years of age), administered IV plus a 5-HT3 antagonist."
            }, 
            {
                "arm_group_label": "Fosaprepitant 20 mg", 
                "arm_group_type": "Experimental", 
                "description": "Cycle 1: Fosaprepitant 20 mg (or weight-adjusted equivalent for children <12 years of age), administered IV plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 150 mg (or weight-adjusted equivalent for children <12 years of age), administered IV plus a 5-HT3 antagonist."
            }, 
            {
                "arm_group_label": "Ondansetron", 
                "arm_group_type": "Active Comparator", 
                "description": "Cycle 1: Matching Placebo to fosaprepitant, administered IV plus ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), administered IV. Optional Cycles 2-6: Fosaprepitant 150 mg (or weight-adjusted equivalent for children <12 years of age), administered IV plus a 5-HT3 antagonist."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the appropriate dosing regimen of fosaprepitant,\n      when administered with ondansetron (with or without dexamethasone), for the prevention of\n      CINV in children from birth to 17 years of age. Fosaprepitant is a prodrug to aprepitant.\n      All participants who complete the randomized Cycle 1 may elect to receive open-label\n      fosaprepitant during optional Cycles 2-6."
        }, 
        "brief_title": "Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029)", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Chemotherapy-induced Nausea and Vomiting", 
        "condition_browse": {
            "mesh_term": [
                "Nausea", 
                "Vomiting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Is 0 (at least 37 weeks gestation) to 17 years of age\n\n          -  Scheduled to receive chemotherapeutic agent(s) associated with moderate, high, or\n             very high risk of emetogenicity for no more than 5 consecutive days for a documented\n             malignancy, or a chemotherapy regimen not previously tolerated due to vomiting\n\n          -  Expected to receive ondansetron as part of antiemetic regimen (Cycle 1); Expected to\n             receive a 5-HT3 antagonist as part of antiemetic regimen (Cycles 2-6)\n\n          -  If female and has begun menstruating, must have a negative pregnancy test prior to\n             study participation and agree to remain abstinent or use a barrier form of\n             contraception\n\n          -  Predicted life expectancy of >=3 months\n\n          -  Pre-existing functioning central venous catheter\n\n          -  Weight >=3rd percentile for age and gender (and >=3.0 kg)\n\n        Exclusion Criteria:\n\n          -  Vomited in the 24 hours prior study drug administration (Cycle 1)\n\n          -  Current user of any illicit drugs (including marijuana) or current evidence of\n             alcohol abuse\n\n          -  Scheduled to receive stem cell rescue therapy in conjunction with study related\n             course(s) of emetogenic chemotherapy\n\n          -  Received or will receive radiation therapy to the abdomen or pelvis in the week prior\n             to study drug administration and/or during the course of the study\n\n          -  Pregnant or breast feeding\n\n          -  Allergic to fosaprepitant, aprepitant, ondansetron, or any other 5-HT3 antagonist\n\n          -  Has a symptomatic central nervous system (CNS) tumor causing nausea and/or vomiting\n\n          -  Has an active infection, congestive heart failure, slow heart rate, or other\n             uncontrolled disease other than cancer\n\n          -  Mentally incapacitated or has a significant emotional or psychiatric disorder\n\n          -  Known history of QT prolongation or is taking any medication known to lead to QT\n             prolongation\n\n          -  Taking other excluded medications\n\n          -  Participated in any previous study of aprepitant or fosaprepitant, or taken an\n             investigational drug within 4 weeks prior to study participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "256", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697579", 
            "org_study_id": "0517-029", 
            "secondary_id": "2012-002340-24"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fosaprepitant 150 mg", 
                "description": "Administered IV as a single dose", 
                "intervention_name": "Fosaprepitant 150 mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Fosaprepitant dimeglumine", 
                    "MK-0517", 
                    "EMEND\u00ae for Injection"
                ]
            }, 
            {
                "arm_group_label": "Fosaprepitant 60 mg", 
                "description": "Administered IV as a single dose", 
                "intervention_name": "Fosaprepitant  60 mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Fosaprepitant dimeglumine", 
                    "MK-0517", 
                    "EMEND\u00ae for Injection"
                ]
            }, 
            {
                "arm_group_label": "Fosaprepitant 20 mg", 
                "description": "Administered IV as a single dose", 
                "intervention_name": "Fosaprepitant  20 mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Fosaprepitant dimeglumine", 
                    "MK-0517", 
                    "EMEND\u00ae for Injection"
                ]
            }, 
            {
                "arm_group_label": "Ondansetron", 
                "description": "Administered IV as a single dose", 
                "intervention_name": "Placebo Fosaprepitant", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Fosaprepitant 150 mg", 
                    "Fosaprepitant 60 mg", 
                    "Fosaprepitant 20 mg", 
                    "Ondansetron"
                ], 
                "description": "Administered IV", 
                "intervention_name": "Ondansetron", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Ondansetron hydrochloride", 
                    "Zofran\u00ae Injection"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ondansetron", 
                "Aprepitant"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "Call for Information (Investigational Site 0122)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Call for Information (Investigational Site 0121)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Call for Information (Investigational Site 0002)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78723"
                    }, 
                    "name": "Call for Information (Investigational Site 0005)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84113"
                    }, 
                    "name": "Call for Information (Investigational Site 0004)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alfredo Wilkinson", 
                    "phone": "54 11 4796 8200"
                }, 
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina"
                    }, 
                    "name": "Merck Sharp & Dohme (Argentina) Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Karl Boegl", 
                    "phone": "43 126044130"
                }, 
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria"
                    }, 
                    "name": "MSD \u00fdterreich GmbH"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ricardo Germano", 
                    "phone": "55 11 51897942"
                }, 
                "facility": {
                    "address": {
                        "city": "Sao Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "MSD Brasil"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Medical Information Centre / Centre de l'information medicale de Merck Canada", 
                    "phone": "514-428-8600 / 1-800-567-2594"
                }, 
                "facility": {
                    "address": {
                        "city": "Kirkland", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H9H 3L1"
                    }, 
                    "name": "Merck Canada"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Francesca Carvajal", 
                    "phone": "57 1219109011090"
                }, 
                "facility": {
                    "address": {
                        "city": "Bogota", 
                        "country": "Colombia"
                    }, 
                    "name": "MDS Colombia SAS"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrius Bacevicius", 
                    "phone": "370 52780243"
                }, 
                "facility": {
                    "address": {
                        "city": "Tallinn", 
                        "country": "Estonia"
                    }, 
                    "name": "Merck Sharp & Dohme OU"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "German Medical Information Center", 
                    "phone": "49 800 673 673 673"
                }, 
                "facility": {
                    "address": {
                        "city": "Haar", 
                        "country": "Germany"
                    }, 
                    "name": "Merck Sharp & Dohme GmbH"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Platon Peristaris", 
                    "phone": "30 2109897322"
                }, 
                "facility": {
                    "address": {
                        "city": "Alimos", 
                        "country": "Greece"
                    }, 
                    "name": "Vianex, S.A. / MSD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Simona Martinkova", 
                    "phone": "36 1 457 8522"
                }, 
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "MSD Pharma Hungary Kft."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Patrizia Nardini", 
                    "phone": "39 06 361911"
                }, 
                "facility": {
                    "address": {
                        "city": "Rome", 
                        "country": "Italy"
                    }, 
                    "name": "MSD Italia S.r.l."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cem Ozesen", 
                    "phone": "90 212 3361260"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "MSD Korea LTD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Andrius Bacevicius", 
                    "phone": "370 52780243"
                }, 
                "facility": {
                    "address": {
                        "city": "Vilnius", 
                        "country": "Lithuania"
                    }, 
                    "name": "UAB \"Merck Sharp & Dohme\""
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Oscar Espinoza", 
                    "phone": "(51-1) 411-5100"
                }, 
                "facility": {
                    "address": {
                        "city": "Lima", 
                        "country": "Peru"
                    }, 
                    "name": "Merck Sharp & Dohme, Peru S.R.L."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ana Maria Nogueira", 
                    "phone": "351-21-4465890"
                }, 
                "facility": {
                    "address": {
                        "city": "Paco D'arcos", 
                        "country": "Portugal"
                    }, 
                    "name": "Merck Sharp & Dohme Lda."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eran Gefen", 
                    "phone": "38 (044) 393 74 80"
                }, 
                "facility": {
                    "address": {
                        "city": "Bucharest", 
                        "country": "Romania"
                    }, 
                    "name": "Merck Sharp & Dohme Romania SRL"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Maria Koroleva", 
                    "phone": "7 0959410000"
                }, 
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Merck Sharp & Dohme IDEA, Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Khanyi Mzolo", 
                    "phone": "27 11 655 3140"
                }, 
                "facility": {
                    "address": {
                        "city": "Midrand", 
                        "country": "South Africa"
                    }, 
                    "name": "MSD (Pty) LTD South Africa"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Cesar Sanz Rodriguez", 
                    "phone": "34 913210600"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Merck Sharp and Dohme de Espana S.A."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alev Eren", 
                    "phone": "90 212 336 12 63"
                }, 
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey"
                    }, 
                    "name": "Merck Sharp & Dohme Ilaclari Ltd. Sti"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Paul Robinson", 
                    "phone": "44 1992452396"
                }, 
                "facility": {
                    "address": {
                        "city": "Hoddesdon", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Merck Sharp & Dohme Ltd."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Austria", 
                "Brazil", 
                "Canada", 
                "Colombia", 
                "Estonia", 
                "Germany", 
                "Greece", 
                "Hungary", 
                "Italy", 
                "Korea, Republic of", 
                "Lithuania", 
                "Peru", 
                "Portugal", 
                "Romania", 
                "Russian Federation", 
                "South Africa", 
                "Spain", 
                "Turkey", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Emetogenic Chemotherapy", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Aprepitant Area Under the Curve (AUC) from 0 to \u221e hours (0-\u221e)", 
                "safety_issue": "No", 
                "time_frame": "Up to 25 hours postdose"
            }, 
            {
                "measure": "Aprepitant Maximum Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 25 hours postdose"
            }, 
            {
                "measure": "Time to Aprepitant Cmax (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 25 hours postdose"
            }, 
            {
                "measure": "Aprepitant Terminal Phase Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "Up to 25 hours postdose"
            }, 
            {
                "measure": "Aprepitant Apparent Total Body Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Up to 25 hours postdose"
            }, 
            {
                "measure": "Percentage of Participants Who Experience At Least One Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 14 days postdose"
            }
        ], 
        "removed_countries": {
            "country": [
                "Chile", 
                "Switzerland", 
                "Taiwan"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697579"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}